Ignite Creation Date:
2024-05-05 @ 11:47 PM
Last Modification Date:
2024-10-26 @ 10:39 AM
Study NCT ID:
NCT01413516
Status:
COMPLETED
Last Update Posted:
2023-11-14
First Post:
2011-08-03
Brief Title:
Varenicline In-Patient Study
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
A Two-Part Pilot Study of Dosing Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VIP
Brief Summary:
This Investigator Initiated Research Award IIR Award WS981308 is a two-part pilot study that aims to examine acceptability and feasibility of varenicline use during an acute 72-hr smoke-free hospitalization Part 1 and 4-weeks post-hospitalization Part 2
Detailed Description:
The sample will be hospitalized patients smoking at least 10 cigarettesday prior to hospitalization Intention to quit smoking will not be required for study participation Using a double-blinded placebo-controlled randomized design participants will receive varenicline 05 mg BID as tolerated or placebo during their hospitalization Part 1 and will continue their study medication placebo or active drug for 4 weeks post-hospitalization Part 2 Abstinence status will be examined at 4 weeks post-hospitalization
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None